Funding for this research was provided by:
Shire International GmbH
Shionogi & Co., Ltd
Received: 26 March 2020
Accepted: 14 September 2020
First Online: 2 October 2020
Change Date: 22 December 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: This study was approved by the following local ethics committee: Mizuo Clinic Institutional Review Board (IRB); Ehime University Hospital IRB; IHL Shinagawa East One Medical Clinic IRB; Dr. Mano Medical Clinic IRB; Odori Park Mental Clinic IRB; Tokyo Midtown Clinic IRB; Tokyo-Eki Center-Building Clinic IRB; Riverside Internal and Circulatory Medical Clinic IRB; Goryokai Hospital IRB; Himorogi Psychiatric Institute IRB; Nanko Clinic of Psychiatry IRB; Iwata Buddy’s Clinic IRB; Suzuki Internal and Circulatory Medical Clinic IRB; Kojinkai Sapporo Skin Clinic IRB; Shoda Hospital IRB; Kondo Hospital IRB; Tomisaka Clinic IRB; Yokohama Sakae Kyosai Hospital IRB; Hokkaido University Hospital IRB; Yamate Dermatological Clinic IRB; Chibune General Hospital IRB; IRB of Showa University Karasuyama Hospital; Yoyogi Mental Clinic IRB; Tokai University Hospital IRB; The Jikei University Hospital IRB for Medicinal Products; Non-Profit Organization Tokyo Allergy and Respiratory Disease Research Institute IRB; Review Board of Human Rights and Ethics for Clinical Studies; Nara Medical University Hospital IRB; University of Fukui Hospital IRB; Hayashi Diabetes Clinic IRB. All patients provided written informed consent before participating in the study.
: Not applicable.
: AI has received honoraria and other payments from Eisai, Eli Lilly Japan, Janssen Japan, Kyowa, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD K.K., Otsuka, Pfizer Japan, Sumitomo Dainippon Pharma, and Yoshitomiyakuhin Corporation. KS has received honoraria and other payments from Eli Lilly Japan, Hisamitsu, Janssen Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka, Shionogi, Shire Japan (now part of the Takeda group of companies), Sumitomo Dainippon Pharma, Taisho, and Yoshitomiyakuhin Corporation. MF and DO are employees of and own shares in Shionogi. HI has received honoraria and other payments from AbbVie GK, Eli Lilly Japan, Hisamitsu Pharmaceutical, Janssen Japan, Meiji Seika Pharma, Otsuka, Shionogi, and Taisho.